ITEOS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.6 USD | +0.28% |
|
+2.61% | -3.20% |
| Mar. 13 | Top Premarket Decliners | MT |
| Mar. 12 | JPMorgan Adjusts Price Target on iTeos Therapeutics to $27 From $29, Maintains Overweight Rating | MT |
Chart calendar iTeos Therapeutics, Inc.
d81bb92888ddf3a.7qdDdM_zUbmnfeGPC-NO05LKAi_1r-egiedXdtDJhH8.lOIwE_uBIcj9JNnOeZUq56WsUX2E8NTj4agVFZf9yyuJyio3v78G95c7uA~725fd0716de9e4c6935af05189ec9eb4
Upcoming events on iTeos Therapeutics, Inc.
Past events on iTeos Therapeutics, Inc.
| 2024-04-07 04:30 pm | American Association for Cancer Research Meeting - Abstract No - 734 |
| 2024-03-10 | Leerink Partners Global Biopharma Conference |
| 2024-03-06 01:30 pm | TD Cowen Health Care Conference |
| 2024-03-06 07:00 am | Q4 2023 Earnings Release |
| 2024-01-10 06:00 pm | JPMorgan Healthcare Conference |
| 2023-11-28 01:30 pm | Piper Sandler Healthcare Conference - Fireside Chat |
| 2023-11-07 07:00 am | Q3 2023 Earnings Release |
| 2023-09-27 08:35 am | Cantor Global Healthcare Conference |
| 2023-09-13 12:30 pm | H.C. Wainwright Global Investment Conference |
| 2023-08-08 07:00 am | Q2 2023 Earnings Release |
| 2023-06-13 09:00 am | Annual General Meeting |
| 2023-05-10 07:01 am | Q1 2023 Earnings Release |
| 2023-04-13 | American Association for Cancer Research Meeting - Poster No - EOS-850 |
| 2023-03-15 07:00 am | Q4 2022 Earnings Release |
| 2023-03-07 09:10 am | Cowen Health Care Conference |
| 2023-02-14 10:00 am | SVB Securities Global Biopharma Conference |
| 2023-01-10 11:15 am | JP Morgan Healthcare Conference |
| 2022-11-29 04:30 pm | Piper Sandler Healthcare Conference |
| 2022-11-10 04:01 pm | Q3 2022 Earnings Release |
| 2022-08-10 04:01 pm | Interim 2022 Earnings Release |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | 345 190 81.72% | 268 258 3.57% | 12,6 20,1 -37.27% | 3,15 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | -44,7 -45,0 0.66% | 246 124 97.94% | 127 118 7.73% | 0,00 0,00 - | 0,00 |
|
EBIT Million USD | Released Forecast Spread | -28,0 | -45,2 -46,1 1.8% | 245 91,6 167.33% | 126 109 15.66% | -151 -144 -5.04% | -195 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -38,1 -40,9 6.82% | 256 88,6 189.31% | 149 126 17.73% | -109 -113 3.58% | -164 |
|
Net income Million USD | Released Forecast Spread | -22,5 | -43,4 -43,1 -0.67% | 215 77,5 176.86% | 96,7 90,4 6.93% | -113 -124 9.22% | -164 |
|
EPS USD | Released Forecast Spread | 0,00 | -2,88 -2,35 -22.74% | 5,68 2,09 171.56% | 2,56 2,40 6.83% | -3,15 -3,40 7.47% | -4,47 |
| Announcement Date | 22/05/20 | 24/03/21 | 23/03/22 | 15/03/23 | 06/03/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 241 85,5 181.43% | 153 63,3 140.95% | 41,7 85,6 -51.25% | 19,5 41,6 -53.2% | 53,9 40,9 31.72% | 12,6 6,90 82.57% | 0,00 0,00 - | 0,00 0,00 - | 0,00 7,40 - | 0,00 | 1,50 | 1,50 | 0,00 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | 214 93,0 129.75% | 3,53 4,00 -11.75% | -15,0 -1,00 -1400% | 17,6 -6,00 393.43% | -24,7 -38,0 34.98% | -42,4 -39,0 -8.71% | -43,1 -44,0 2.15% | |||||||
|
EBIT Million USD | Released Forecast Spread | 214 60,3 253.99% | 121 23,9 404.77% | 3,34 40,8 -91.83% | -15,2 0,73 -2169.41% | 17,4 -3,47 601.13% | -24,9 -30,2 17.38% | -42,6 -39,8 -7.06% | -43,3 -45,1 3.93% | -40,1 -33,0 -21.58% | -44,3 | -45,6 | -49,2 | -55,3 | -64,8 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 224 52,7 324.95% | 120 30,6 290.11% | 8,44 40,8 -79.31% | -1,99 3,50 -156.73% | 22,7 1,56 1358.78% | -14,4 -26,2 45.19% | -33,1 -32,6 -1.58% | -33,4 -38,2 12.57% | -28,2 -28,4 0.75% | -36,8 | -38,1 | -41,4 | -47,7 | -55,0 |
|
Net income Million USD | Released Forecast Spread | 185 49,7 272.35% | 69,6 30,3 129.71% | 5,63 46,2 -87.83% | 0,99 2,46 -59.7% | 20,5 5,48 273.52% | -15,6 -35,1 55.65% | -34,3 -36,9 7.15% | -32,2 -43,1 25.2% | -30,6 -37,7 19.02% | -36,8 | -38,1 | -41,4 | -47,7 | -55,0 |
|
EPS USD | Released Forecast Spread | 4,89 1,28 282.81% | 1,82 0,80 128.93% | 0,15 1,20 -87.53% | 0,03 0,07 -59.37% | 0,55 0,13 332.36% | -0,44 -0,99 55.74% | -0,96 -1,03 6.84% | -0,90 -1,20 25.25% | -0,85 -1,03 17.73% | -1,02 | -1,04 | -1,13 | -1,29 | -1,60 |
| Announcement Date | 23/03/22 | 12/05/22 | 10/08/22 | 10/11/22 | 15/03/23 | 10/05/23 | 08/08/23 | 07/11/23 | 06/03/24 | - | - | - | - | - |
More events
Past sector events for iTeos Therapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ITOS Stock
- Calendar iTeos Therapeutics, Inc.
